Other Events ·
AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy for metastatic…
AZNCFAstrazeneca PLC
AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy for metastatic non-small cell lung cancer (mNSCLC) with PD-L1 <50%. The Independent Data Monitoring Committee recommended termination, concluding the combination was unlikely to meet primary endpoints for progression-free or overall survival in patients with PD-L1 negative tumors (<1%). The trial enrolled 895 patients across 25 countries. Other Phase III volrustomig trials in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma continue as planned. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines.